Publications

Christopher Johns, Hala Borno, Samuel L. Washington, Wesley Robinson, Miriam Perales, Rahul Raj Aggarwal, Rohit Bose, Jonathan Chou, Arpita Desai, Kelly N. Fitzgerald, Terence W. Friedlander, Vadim S Koshkin, Ivan de Kouchkovsky, Elizabeth Pan, Eric J. Small, Noah Spector Younger, Xiaolin Zhu, Franklin W. Huang, Daniel H. Kwon. Development of a culturally tailored educational tool designed to increase access to somatic testing among Black men with metastatic prostate cancer (mPCa). Journal of Clinical Oncology. 2025. PMID:

Tanya Jindal, Emily Wu, Sara Topalovic, Nana Shakhnazaryan, Sylvia Zhang, Hala Borno. Enhancing clinical trial site efficiency and unlocking patient access to clinical trials using technology-enabled pre-screening. Journal of Clinical Oncology. 2025. PMID:

Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184

Kawasaki K, Salehi S, Zhan YA, Chen K, Lee JH, Salataj E, Zhong H, Manoj P, Kinyua D, Mello BP, Sridhar H, Tischfield SE, Linkov I, Ceglia N, Zatzman M, Havasov E, Shah NJ, Meng F, Loomis B, Bhanot UK, Redin E, de Stanchina E, Hamard PJ, Koche RP, McPherson A, Quintanal-Villalonga Á, Shah SP, Massagué J, Rudin CM. FOXA2 promotes metastatic competence in small cell lung cancer. Nature communications. 2025. PMID: 40419484

Menzies AM, Long GV, Kohn A, Tawbi H, Webe J, Flaherty K, McArthur GA, Ascierto PA, Pfluger Y, Lewis K, Tsai KK, Hamid O, Prenen H, Fein L, Wang E, Guenzel C, Zhang F, Kleh JF, di Pietro A, Davies MA. A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis. Future oncology (London, England). 2025. PMID: 40418081

Stinchcombe TE, Fleming GF, Craddock C, Ko AH, O'Reilly EM, Maki RG. Early-Phase Trials in Journal of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40403204

St-Laurent MP, Singh P, McConkey DJ, Lucia MS, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Meeks JJ, Caruso VM, Ward CT, Mazzarella BC, Phillips KG, Bicocca VT, Levin TG, Lerner SP, Black PC. Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. European urology. 2025. PMID: 40404526

Hillege LE, Trepka KR, Guthrie BGH, Fu X, Aarnoutse R, Paymar MR, Olson C, Zhang C, Ortega E, Ramirez L, de Vos-Geelen J, Valkenburg-van Iersel L, van Hellemond IEG, Baars A, Vestjens JHMJ, Penders J, Deutschbauer A, Atreya CE, Kidder WA, Smidt ML, Ziemons J, Turnbaugh PJ. Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity. mBio. 2025. PMID: 40391895

Bierer SB, Beck Dallaghan G, Borges NJ, Brondfield S, Fung CC, Huggett KN, Teal CR, Thammasitboon S, Colbert CY. Moving Beyond Simplistic Research Design in Health Professions Education: What a One-Group Pretest-Posttest Design Will Not Prove. MedEdPORTAL : the journal of teaching and learning resources. 2025. PMID: 40395408

Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC, Mody K, Gong J, Crysler OV, Sukeepaisarnjaroen W, Lipatov O, Morimoto M, Archambeaud I, Burgio V, Phuong LTT, Chao Y, Peron JM, Berres ML, Ko YJ, Ran D, Makowsky M, Negro A, Abou-Alfa GK. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. Hepatology (Baltimore, Md.). 2025. PMID: 40384092

Corti C, Rugo HS, Tolaney SM. Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2025. PMID: 40367401

Kasap C, Izgutdina A, Patiño-Escobar B, Kang AS, Chilakapati N, Akagi N, Manoj AM, Johnson H, Rashid T, Werner J, Barpanda A, Geng H, Lin YT, Rampersaud S, Gil-Alós D, Sobh A, Dupéré-Richer D, Aleman A, Wicaksono G, Kelii KMK, Dalal R, Ramos E, Vijayanarayanan A, Lakhani K, Salangsang F, Phojanakong P, Camara Serrano JA, Zakraoui O, Tariq I, Chari A, Chung A, Kumar AD, Martin T, Wolf JL, Wong S, Steri V, Shanmugam M, Boise LH, Kortemme T, Parekh S, Stieglitz E, Licht JD, Karlon W, Barwick BG, Wiita A. Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells. Blood. 2025. PMID: 40359480

Khozin S, Dreyer NA, Galante D, Liu R, Neumann P, Nussbaum N, O'Shaughnessy J, Patt D, Rimawi M, Rugo H, Tolaney SM, Weiss M, Brufsky A. Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank. Advances in therapy. 2025. PMID: 40354012

Vijay V, Karisani N, Shi L, Hung YH, Vu P, Kattel P, Kenney L, Merritt J, Adil R, Wu Q, Zhen Y, Morris R, Kreuzer J, Kathiresan M, Herrera Lopez XI, Ellis H, Gritti I, Lecorgne L, Farag I, Popa A, Shen W, Kato H, Xu Q, Balasooriya ER, Wu MJ, Wan J, Kondo H, Chaturantabut S, Raghavan S, Hall MD, Patnaik S, Shen M, Kelley RK, Cleary JM, Lawrence MS, Root DE, Patra KC, Silveira VS, Benes CH, Deshpande V, Juric D, Sellers WR, Ferrone CR, Haas W, Vazquez F, Getz G, Bardeesy N. Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targets. Cancer discovery. 2025. PMID: 40353839

Perez K, Del Rivero J, Kennedy EB, Basu S, Chauhan A, Connolly HM, Dasari AN, Gangi A, Clarke CN, Hallet J, Howe JR, Grady E, Ivanidze J, Mittra ES, White SB, Raj NP, Vijayvergia N, Lewis MA, Chan JA, Kunz PL, Mailman J, Arshad J, Soares HP, Singh S, Chandrasekharan C, Soulen MC, Janson ET, Halfdanarson TR, Strosberg JR, Bergsland EK. Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO oncology practice. 2025. PMID: 40344544

Ueno NT, Cottone F, Dunton K, Jacot W, Yamashita T, Sohn J, Tokunaga E, Prat A, Tsurutani J, Park YH, Rugo HS, Xu B, Cardoso F, Mitri Z, Mahtani R, Aguilar CO, Xiao F, Harbeck N, Cameron DA, Modi S. Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC. The oncologist. 2025. PMID: 40349139

Muhsen IN, Roloff GW, Faramand RG, Othman T, Valtis YK, Kopmar NE, Dekker SE, Connor M, Mercadal S, O'Connor TE, Dykes KC, Ahmed M, Jeyakumar N, Zhang A, Miller K, Sutherland KC, Guzowski C, Gupta VK, Majhail NS, Battiwalla M, Solh MM, Malik SA, Mathews J, Oliai C, Shaughnessy PJ, Mountjoy L, Lee CJ, Logan AC, Tsai SB, Leonard JT, Schwartz MS, Sasine JP, Kumaran M, Frey NV, Park JH, Koura D, Cassaday RD, Shah BD, Aldoss I, Muffly LS, Hill LC. Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement. Blood advances. 2025. PMID: 40334068

Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leukemia & lymphoma. 2025. PMID: 40329916

Phi LTH, Cheng Y, Funakoshi Y, Bertucci F, Finetti P, Van Laere SJ, Zou F, Long JP, Ogata S, Krishnamurthy S, Reuben JM, Foulks JM, Warner SL, Rosenbluth JM, Sood AK, Tripathy D, Ueno NT, Wang X. AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization. Breast cancer research : BCR. 2025. PMID: 40329335

Chi KN, Castro E, Attard G, Smith MR, Sandhu S, Efstathiou E, Roubaud G, Small EJ, de Santana Gomes AP, Rathkopf DE, Saad M, Gurney H, Jung W, Kim W, Dibaj S, Wu D, Zhang J, Lopez-Gitlitz A, Francis P, Olmos D. Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial. European urology oncology. 2025. PMID: 40328571